Clinical Genomics in Myeloid Malignancies (AML)
This information was originally presented on September 21, 2013, at the NCCN 8th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Explain the role of genomics/molecular markers in the risk stratification of patients with AML
Richard M. Stone, MD
Dana-Farber/Brigham and Women's Cancer Center
- 0.50 Participation
- 0.41 Nurse
- 0.50 Pharmacist
- 0.50 Physician